

SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised and that there is no change in the number of A Shares in issue between the Latest Practicable Date and the [REDACTED]), the following persons will have interests and/or short positions in the Shares or underlying Shares which would be required to be disclosed to us and the SEHK pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or will be, directly or indirectly, entitled to exercise, or control the exercise of, 10% or more of the voting power at any general meeting of our Company:

Shareholder	Capacity/Nature of interest ⁽⁴⁾	Description of Shares	Number of Shares directly or indirectly held	As of the Latest Practicable Date		Immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised and that there is no change in the number of A Shares in issue between the Latest Practicable Date and the [REDACTED])	
				Approximate percentage of shareholding in our A Shares	Approximate percentage of shareholding in our total issued Shares	Approximate percentage of shareholding in our A Shares	Approximate percentage of shareholding in our total issued Shares ⁽¹⁾
Dr. Zhu	Beneficial owner	A Shares	298,159,400	72.22%	72.22%	72.22%	[REDACTED]%
	Interested in treasury shares ⁽³⁾	A Shares	1,558,877	0.38%	0.38%	0.38%	[REDACTED]%
OAP III (HK) Limited ⁽²⁾	Beneficial owner	A Shares	24,398,433	5.91%	5.91%	5.91%	[REDACTED]%
OrbiMed Asia Partners III, L.P. ⁽²⁾	Interest held by controlled corporation	A Shares	24,398,433	5.91%	5.91%	5.91%	[REDACTED]%
OrbiMed Asia GP III, L.P. ⁽²⁾	Interest held by controlled corporation	A Shares	24,398,433	5.91%	5.91%	5.91%	[REDACTED]%
OrbiMed Advisors III Limited ⁽²⁾	Interest held by controlled corporation	A Shares	24,398,433	5.91%	5.91%	5.91%	[REDACTED]%

Notes:

- (1) The calculation is based on 412,873,817 A Shares (including 1,558,877 A Shares being held as treasury Shares repurchased by our Company) and [REDACTED] H Shares in issue.
- (2) OAP III (HK) Limited (“OAP III”) beneficially owns 24,398,433 A Shares. OAP III is a limited company organized under the laws of Hong Kong. OAP III is wholly owned by OrbiMed Asia Partners III, L.P. (“OAP Asia III”). OAP Asia III is an exempted limited partnership incorporated under the laws of the Cayman Islands. OAP Asia III’s general partner is OrbiMed Asia GP III, L.P. (“OAP III GP”), and OAP III GP’s general partner is OrbiMed Advisors III Limited (“Advisors III”). OrbiMed Advisors LLC (“OrbiMed Advisors”) is the advisory company of OAP Asia III. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom is an Independent Third Party.
- (3) As of the Latest Practicable Date, our Company had repurchased an aggregate of 1,558,877 A Shares, all of which were held as treasury Shares. As such, under the SFO, Dr. Zhu Yi, who controls more than one third of the voting power at the general meetings of our Company, would be taken to have an interest in such repurchased A Shares held by our Company.
- (4) All interests stated represent long positions.

Save as otherwise disclosed herein, our Directors are not aware of any other person who will, immediately following the completion of the [REDACTED] (assuming the [REDACTED] is not exercised and that there is no change in the number of A Shares in issue between the Latest Practicable Date and the [REDACTED]), have any interest and/or short positions in the Shares of our Company which would fall to be disclosed to us pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, who are, directly or indirectly, entitled to exercise, or control the exercise of, 10% or more of the voting power at any general meeting of any other member of our Group.